Počet záznamů: 1

Preclinical Evaluation of (177)Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor-Overexpressing Tumors

  1. 1.
    0365501 - UJF-V 2012 RIV US eng J - Článek v odborném periodiku
    Beckford, Denis R. - Eigner, Sebastian - Beran, Miloš - Eigner-Henke, Kateřina - Lázníček, M. - Melichar, František - Chinol, M.
    Preclinical Evaluation of (177)Lu-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor-Overexpressing Tumors.
    Cancer Biotherapy and Radiopharmaceuticals. Roč. 26, č. 3 (2011), s. 287-297 ISSN 1084-9785
    Grant CEP: GA MŠk OE08018
    Výzkumný záměr: CEZ:AV0Z10480505
    Klíčová slova: EGFR * (177)Lu * monoclonal antibodies * Nimotuzumab
    Kód oboru RIV: FR - Farmakologie a lékárnická chemie
    Impakt faktor: 1.787, rok: 2011

    Background: The humanized monoclonal antibody Nimotuzumab (h-R3) has demonstrated an exceptional and better clinical profile than other monoclonal antibodies for immunotherapy of epidermal growth factor receptor-overexpressing tumors. This work deals with the preparation and radiolabeling optimization of (177)Lu-Nimotuzumab and their preclinical evaluation. Methods: Nimotuzumab was conjugated with S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraazacyclododecane tetraacetic acid (p-SCN-Bn-DOTA), testing different molar ratios. The immunoconjugates were characterized. The radiolabeling with (177)Lu was optimized.
    Trvalý link: http://hdl.handle.net/11104/0200730